Topic resource collection
Approved comparison material connected to this topic.
268 resourcesRead both sides
KPV NF-κB inhibition in mast cells Anti-inflammatory Preclinical + case reports Topical Strongest evidence for erythema reduction; requires permeation enhancer BPC-157 Vascular stabilization, endothelial repair Angiogenesis modul…
Before selecting peptides for a research protocol, understanding their distinct mechanisms, dosing requirements, and evidence base is essential. BPC-157 Angiogenesis, mitochondrial stabilisation, oxidative stress reduction 10 mcg…
Before writing this table, here's what it shows: the only two peptides with documented circadian-relevant mechanisms (Epitalon and DSIP) compared against commonly marketed alternatives that lack circadian specificity. The 'Profes…
Tirzepatide Dual GLP-1/GIP agonist GLP-1R, GIPR ~5 days Metabolic research, insulin sensitivity studies Strongest metabolic efficacy data among dual agonists; 20.9% mean weight reduction in SURMOUNT-1 trial Survodutide Dual GLP-1…
BPC-157 eNOS stabilization, VEGF upregulation, inflammatory cytokine suppression Acute (0–72 hours) 10 μg/kg Intraperitoneal BBB permeability, lesion volume, motor recovery Best for focal injuries with prominent vascular disrupti…
BPC-157 VEGF upregulation, angiogenesis, nitric oxide signaling 34% increase in nerve conduction velocity in diabetic rat models (12 weeks) Subcutaneous injection Strongest vascular repair evidence; most studied in peripheral ner…
BPC-157 VEGFR2 upregulation → angiogenesis, mucosal blood flow restoration Ethanol-induced, ischemia-reperfusion injury 10–50 mcg/kg IP or oral daily for 7–14 days Minimal effect in NSAID models where vascular injury is secondary…
GLP-1 Agonists (Semaglutide, Tirzepatide) Incretin receptor activation → insulin secretion, gastric emptying delay Hyperinsulinemia, androgen excess Strong clinical translation. Phase 3 data in PCOS populations Best for insulin-a…
MOTS-c Mitochondrial biogenesis upregulation via PGC-1alpha activation Complex I function, ROS reduction Intranasal, intraperitoneal 5–15 mg/kg IP 3×/week Reduced ROS, improved mitochondrial respiration in aged brain tissue (USC …
Semax BDNF upregulation via TrkB activation Synaptic plasticity, dendritic spine formation 10–100 μM (in vitro), 50–500 μg/kg (in vivo) Stable in PBS for 7 days at 4°C; degrades rapidly above pH 8.0 Best choice for studying synap…
BPC-157 Angiogenesis, mucosal protection VEGFR2, FAK-paxillin signaling 14–21 days for 60–70% lesion reduction 40+ preclinical studies in gastric injury models Strongest evidence for direct tissue repair; gold standard for gastri…
BPC-157 VEGF upregulation, collagen synthesis enhancement, inflammatory cytokine suppression 10 mcg/kg daily (subcutaneous) in animal models 28 days at 2–8°C 4–12 weeks Most studied for tendon-bone healing; angiogenic effects tra…
BPC-157 250–500mcg Daily (subcutaneous or IM) VEGF upregulation, angiogenesis, fibroblast proliferation Moderate. Rat tendon models show 70% strength increase at 14 days Small injection volume, daily commitment, requires bacterio…
BPC-157 Epithelial repair, angiogenesis VEGF upregulation, NOS stabilisation Rodent models: 60% faster healing; human case reports positive 250–500 mcg SC daily Most relevant for barrier dysfunction SIBO LL-37 Antimicrobial membr…
This table compares the primary peptides used in testosterone-related research based on mechanism, half-life, dosing frequency, and documented effects on gonadotropin pathways. CJC-1295 (with DAC) GHRH analogue. Stimulates sustai…
Before diving into protocol specifics, this table summarizes the three leading peptides studied for post-viral cognitive impairment. Their mechanisms, administration routes, and what research shows about their efficacy. Semax ACT…
BPC-157 VEGF modulation, nitric oxide pathway regulation Days 0–14 post-injury Reduces collagen III deposition by 25–40% vs controls; accelerates collagen I transition Promotes controlled angiogenesis; reduces vascular permeabili…
BPC-157 Growth hormone receptor activation in fibroblasts; upregulates FAK-paxillin pathway for cell migration and ECM remodelling Proliferative phase (days 7–21) 250–500mcg daily subcutaneous Human clinical trial data absent; do…
BPC-157 GABAergic modulation in basolateral amygdala Intraperitoneal 10 μg/kg daily ~4 hours GABA_A receptor density, freezing behavior in contextual fear conditioning Strongest signal in fear extinction protocols; requires IP ad…
Before selecting a peptide for anxiety research protocols, understanding the mechanistic, temporal, and logistical differences across compounds is essential. The following table compares the three most studied peptides in anxiety…